Skip to main content

TableĀ 3 Upcoming cardiovascular outcomes trials in type 2 diabetes

From: Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Study Drug Comparator Primary endpoint Results
CANVAS Canagliflozin Placebo Major adverse cardiovascular events, including CV death, non-fatal MI, and non-fatal stroke 2017
CARMELINA Linagliptin Placebo Composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for unstable angina pectoris 2018
EXSCEL Exenatide once weekly Placebo Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke 2018
REWIND Dulaglutide Placebo Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke 2018
DECLARE-TIMI 58 Dapagliflozin Placebo Composite endpoint: CV death, MI or ischemic stroke 2019
CAROLINA Linagliptin Glimepiride Composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalisation for unstable angina pectoris 2019
  1. CV cardiovascular, MI myocardial infarction